Dr. David Ripin is the executive vice president of infectious diseases, and the chief science officer at the Clinton Health Access Initiative (CHAI). In these roles, he oversees CHAI’s work on increasing access to medicines and diagnostics for HIV, malaria, tuberculosis, and other disease areas through the use of sustainable market interventions. CHAI’s Access program has successfully implemented agreements with pharmaceutical companies to lower the price of key drugs and diagnostics by up to 80 percent. He also oversees the strategy and work of CHAI’s Malaria program.

Before joining CHAI, he worked at Pfizer, Inc. for ten years as part of the research and development group, focusing on the commercialization and manufacturing of drug candidates.